Ana Motos
Overview
Explore the profile of Ana Motos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corticosteroid and antimicrobial therapy in macrolide-resistant pneumococcal pneumonia porcine model
Motos A, Yang M, Battaglini D, Yang H, Meli A, Bobi J, et al.
Intensive Care Med Exp
. 2025 Feb;
13(1):27.
PMID: 40016489
Background: Streptococcus pneumoniae, a primary cause of community-acquired pneumonia (CAP), is typically treated with β-lactams and macrolides or quinolones. Corticosteroids are now recommended as adjunctive therapy in severe CAP to...
2.
Smit J, Van Der Zee P, Stoof S, van Genderen M, Snijders D, Boersma W, et al.
Lancet Respir Med
. 2025 Feb;
13(3):221-233.
PMID: 39892408
Background: Despite several randomised controlled trials (RCTs) on the use of adjuvant treatment with corticosteroids in patients with community-acquired pneumonia (CAP), the effect of this intervention on mortality remains controversial....
3.
Blok S, Pisani L, Estenssoro E, Ferreira J, Botta M, Motos A, et al.
Am J Trop Med Hyg
. 2025 Jan;
PMID: 39842032
Epidemiology, ventilator management, and outcomes in patients with acute respiratory distress syndrome (ARDS) because of coronavirus disease 2019 (COVID-19) have been described extensively but have never been compared between countries....
4.
Wendel-Garcia P, Ceccato A, Motos A, Franch-Llasat D, Perez-Moreno M, Domenech-Spanedda M, et al.
J Infect
. 2025 Jan;
90(2):106411.
PMID: 39814268
Background: Bacterial pulmonary superinfections develop in a substantial proportion of mechanically ventilated COVID-19 patients and are associated with prolonged mechanical ventilation requirements and increased mortality. Albeit recommended, evidence supporting the...
5.
Piedepalumbo F, Motos A, Blasi F, Torres A
Eur Respir Rev
. 2025 Jan;
34(175).
PMID: 39778921
The systemic use of corticosteroids for patients with severe community-acquired pneumonia (sCAP) remains controversial in clinical practice, particularly in terms of the safety profile of these drugs. This narrative review...
6.
Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia
Calabretta D, Cilloniz C, Gabarrus A, Motos A, Galli F, Ferrer M, et al.
Chest
. 2024 Oct;
PMID: 39461555
Background: The management of nosocomial pneumonia represents a major challenge in the ICU. European guidelines from 2017 proposed an algorithm for the prescription of empirical antimicrobial treatment based on medical...
7.
van der Ven F, Blok S, Azevedo L, Bellani G, Botta M, Estenssoro E, et al.
Respir Res
. 2024 Aug;
25(1):312.
PMID: 39153979
Background: Ventilation management may differ between COVID-19 ARDS (COVID-ARDS) patients and patients with pre-COVID ARDS (CLASSIC-ARDS); it is uncertain whether associations of ventilation management with outcomes for CLASSIC-ARDS also exist...
8.
Guzzardella A, Motos A, Vallverdu J, Torres A
Med Klin Intensivmed Notfmed
. 2023 Dec;
118(Suppl 2):86-92.
PMID: 38051381
Sepsis and septic shock, which are often caused by pneumonia, impact millions of people every year. Despite adequate antibiotic therapy, mortality remains high, up to 45% in septic shock, which...
9.
Barbeta E, Arrieta M, Motos A, Bobi J, Yang H, Yang M, et al.
Crit Care
. 2023 Jun;
27(1):239.
PMID: 37328874
Background: Animal models of acute respiratory distress syndrome (ARDS) do not completely resemble human ARDS, struggling translational research. We aimed to characterize a porcine model of ARDS induced by pneumonia-the...
10.
de Gonzalo-Calvo D, Molinero M, Benitez I, Perez-Pons M, Garcia-Mateo N, Ortega A, et al.
Respir Res
. 2023 Jun;
24(1):159.
PMID: 37328754
Background: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically...